minimal Common Oncology Data Elements (mCODE) Implementation Guide
3.0.0 - STU3 Release United States of America flag

This page is part of the HL7 FHIR Implementation Guide: minimal Common Oncology Data Elements (mCODE) Release 1 - US Realm | STU1 (v3.0.0: STU 3) based on FHIR (HL7® FHIR® Standard) R4. The current version which supersedes this version is 4.0.0. For a full list of available versions, see the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Home
... 2 Patient Information
... 3 Disease Characterization
... 4 Assessment
... 5 Genomics
... 6 Treatments
... 7 Outcomes
... 8 Conformance Expectations
... 9 Identifying In-Scope Patients
... 10 Profile Conformance
... 11 Terminology
... 12 Data Dictionary
... 13 Profiles
... 14 Extensions
... 15 Value Sets
... 16 Code Systems
... 17 Capability Statements
... 18 Artifacts Summary
.... 18.1 mCODE Data Receiver CapabilityStatement: Get in-scope patients (and associated Conditions) using _include
.... 18.2 mCODE Data Receiver CapabilityStatement: Get in-scope patients using reverse chaining
.... 18.3 mCODE Data Receiver: Get Bundle for a Patient
.... 18.4 mCODE Data Receiver: Get Conditions then Patients
.... 18.5 mCODE Data Receiver: Get Patients in Group
.... 18.6 mCODE Data Sender CapabilityStatement: Get in-scope patients (and associated Conditions) using _include
.... 18.7 mCODE Data Sender CapabilityStatement: Get in-scope patients using reverse chaining
.... 18.8 mCODE Data Sender: Get Bundle for a Patient
.... 18.9 mCODE Data Sender: Get Conditions then Patients
.... 18.10 mCODE Data Sender: Get Patients in Group
.... 18.11 Fetch mCODE Patient Bundle for a given Patient
.... 18.12 Search by code:in in Conditions
.... 18.13 Cancer Stage Profile
.... 18.14 Parent for T, N, and M Categories.
.... 18.15 Cancer Disease Status Profile
.... 18.16 Cancer Patient Profile
.... 18.17 Cancer-Related Medication Administration Profile
.... 18.18 Cancer-Related Medication Request Profile
.... 18.19 Cancer-Related Surgical Procedure Profile
.... 18.20 CLL Binet Stage Profile
.... 18.21 CLL Rai Stage Profile
.... 18.22 Comorbidities Profile
.... 18.23 ECOG Performance Status Profile
.... 18.24 Genomic Region Studied Profile
.... 18.25 Genomic Variant Profile
.... 18.26 Genomics Report Profile
.... 18.27 Gynecologic Tumor FIGO Stage Profile
.... 18.28 History of Metastatic Cancer
.... 18.29 Human Specimen Profile
.... 18.30 Karnofsky Performance Status Profile
.... 18.31 Lymphoma Stage Profile
.... 18.32 mCODE Patient Bundle Profile
.... 18.33 mCODE Patient Group Profile
.... 18.34 Melanoma Breslow Depth Stage Profile
.... 18.35 Melanoma Clark Level Profile
.... 18.36 Myeloma ISS Stage Profile
.... 18.37 Myeloma RISS Stage Profile
.... 18.38 Primary Cancer Condition Profile
.... 18.39 Prostate Gleason Grade Group Profile
.... 18.40 Radiotherapy Course Summary Profile
.... 18.41 Radiotherapy Volume Profile
.... 18.42 Secondary Cancer Condition Profile
.... 18.43 TNM Distant Metastases Category Profile
.... 18.44 TNM Primary Tumor Category Profile
.... 18.45 TNM Regional Nodes Category Profile
.... 18.46 TNM Stage Group Profile
.... 18.47 Tumor Marker Test Profile
.... 18.48 Tumor Profile
.... 18.49 Tumor Size Profile
.... 18.50 Body Structure Identifier Profile
.... 18.51 Body Location Qualifier Extension
.... 18.52 Cancer Disease Status Evidence Type Extension
.... 18.53 Histology-Morphology-Behavior Extension
.... 18.54 Laterality Qualifier Extension
.... 18.55 Procedure Intent Extension
.... 18.56 Radiotherapy Dose Delivered To Volume Extension
.... 18.57 Radiotherapy Modality And Technique Extension
.... 18.58 Radiotherapy Modality Extension
.... 18.59 Radiotherapy Number of Sessions Extension
.... 18.60 Radiotherapy Technique Extension
.... 18.61 Related Condition Absent Extension
.... 18.62 Related Condition Extension
.... 18.63 Treatment Termination Reason Extension (deprecated)
.... 18.64 Benign Neoplasm of Brain and CNS Disorder Value Set
.... 18.65 Binet Stage Value Set
.... 18.66 Body Location and Laterality Qualifier Value Set
.... 18.67 Body Location Qualifier Value Set
.... 18.68 Brachytherapy High Dose Rate Electronic Technique Value Set
.... 18.69 Brachytherapy High Dose Rate Technique Value Set
.... 18.70 Brachytherapy Low Dose Rate Temporary Radation Technique Value Set
.... 18.71 Brachytherapy Modality Value Set
.... 18.72 Brachytherapy Permanent Seeds Technique Value Set
.... 18.73 Brachytherapy Pulsed Dose Rate Technique Value Set
.... 18.74 Brachytherapy Radiopharmaceutical Technique Value Set
.... 18.75 Brachytherapy Technique Value Set
.... 18.76 Breslow Depth Stage Value Set
.... 18.77 Cancer Body Location Value Set
.... 18.78 Cancer Disease Status Evidence Type Value Set
.... 18.79 Cancer Disorder Value Set
.... 18.80 Cancer Stage Type Value Set
.... 18.81 Cancer Stage Value Set
.... 18.82 Cancer Staging Method Value Set
.... 18.83 Cancer-Related Surgical Procedure Value Set
.... 18.84 Carbon Ion Beam Technique Value Set
.... 18.85 Carcinoma In-Situ Disorder Value Set
.... 18.86 Clark Level Value Set
.... 18.87 Clinical or Pathologic Modifier
.... 18.88 Condition Status Trend Maximum Value Set
.... 18.89 Condition Status Trend Value Set
.... 18.90 Cytologic Evidence of Malignancy Value Set
.... 18.91 Electron Beam Technique Value Set
.... 18.92 FAB Classification Value
.... 18.93 FIGO Stage Value Set
.... 18.94 FIGO Staging Method Value Set
.... 18.95 Gleason Grade Value Set
.... 18.96 Histology Morphology Behavior Value Set
.... 18.97 History of Metastatic Malignant Neoplasm Value Set
.... 18.98 Human Specimen Type Value Set
.... 18.99 International Staging System (ISS) for Myeloma Stage Value Set
.... 18.100 Laterality Qualifier Value Set
.... 18.101 Lymphoma Stage Value Modifier Value Set
.... 18.102 Lymphoma Stage Value Set
.... 18.103 Lymphoma Staging System Value Set
.... 18.104 Melanoma In-Situ Disorder Value Set
.... 18.105 Neutron Beam Technique Value Set
.... 18.106 Photon Beam Technique Value Set
.... 18.107 Primary Cancer Disorder Value Set
.... 18.108 Primary Malignant Neoplasm Disorder Value Set
.... 18.109 Procedure Intent Value Set
.... 18.110 Proton Beam Technique Value Set
.... 18.111 Radiotherapy Modality Value Set
.... 18.112 Radiotherapy Technique Value Set
.... 18.113 Radiotherapy Treatment Location Qualifier Value Set
.... 18.114 Radiotherapy Treatment Location Value Set
.... 18.115 Radiotherapy Volume Type Value Set
.... 18.116 Rai Stage Value Set
.... 18.117 Rai Staging System Value Set
.... 18.118 Revised International Staging System (ISS) for Multiple Myeloma Stage Value Set
.... 18.119 Secondary Cancer Disorder Value Set
.... 18.120 Specific Diagnosis of Cancer Value Set
.... 18.121 Teleradiotherapy Modality Value Set
.... 18.122 Teleradiotherapy Technique Value Set
.... 18.123 TNM Distant Metastases Category Value Set
.... 18.124 TNM Distant Metastases Maximum Value Set
.... 18.125 TNM Distant Metastases Staging Type Maximum Value Set
.... 18.126 TNM Distant Metastases Staging Type Value Set
.... 18.127 TNM Primary Tumor Category Value Set
.... 18.128 TNM Primary Tumor Maximum Value Set
.... 18.129 TNM Primary Tumor Staging Type Maximum Value Set
.... 18.130 TNM Primary Tumor Staging Type Value Set
.... 18.131 TNM Regional Nodes Category Value Set
.... 18.132 TNM Regional Nodes Maximum Value Set
.... 18.133 TNM Regional Nodes Staging Type Maximum Value Set
.... 18.134 TNM Regional Nodes Staging Type Value Set
.... 18.135 TNM Stage Group Maximum Value Set
.... 18.136 TNM Stage Group Staging Type Maximum Value Set
.... 18.137 TNM Stage Group Staging Type Value Set
.... 18.138 TNM Stage Group Value Set
.... 18.139 TNM Staging Method Value Set
.... 18.140 Treatment Termination Reason Value Set
.... 18.141 Tumor Marker Test Value Set
.... 18.142 Tumor Morphology Code Max Value Set
.... 18.143 Tumor Morphology Code Value Set
.... 18.144 Tumor Size Method Value Set
.... 18.145 Tumor Size Units Value Set
.... 18.146 Requested SNOMED Codes Code System
.... 18.147 TG263 Concept Map
.... 18.148 binet-stage-group-A
.... 18.149 bodyheight-jenny-m-2018-03-06
.... 18.150 bodyweight-jenny-m-2018-03-16
.... 18.151 bodyweight-jenny-m-2018-04-22
.... 18.152 cancer-disease-status-improved
.... 18.153 cancer-disease-status-jenny-m
.... 18.154 cancer-patient-adam-everyman
.... 18.155 cancer-patient-eve-anyperson
.... 18.156 cancer-patient-jenny-m
.... 18.157 cancer-patient-john-anyperson
.... 18.158 cancer-related-comorbidities-jenny-m
.... 18.159 cancer-related-comorbidities-john-anyperson
.... 18.160 cancer-related-medication-admin-cyclophosphamide-jenny-m
.... 18.161 cancer-related-medication-admin-doxorubicin-jenny-m
.... 18.162 cancer-related-medication-admin-paclitaxel-jenny-m
.... 18.163 cancer-related-medication-request-anastrozole-jenny-m
.... 18.164 cancer-related-medication-request-cisplatin
.... 18.165 cancer-related-medication-request-cisplatin-stopped
.... 18.166 cancer-related-medication-request-cyclophosphamide-jenny-m
.... 18.167 cancer-related-medication-request-doxorubicin-jenny-m
.... 18.168 cancer-related-medication-request-gefitinib
.... 18.169 cancer-related-medication-request-paclitaxel-jenny-m
.... 18.170 cancer-related-surgical-procedure-jenny-m
.... 18.171 cancer-related-surgical-procedure-lobectomy
.... 18.172 ecog-performance-status-fully-active
.... 18.173 ecog-performance-status-jenny-m
.... 18.174 family-member-history-aunt-jenny-m
.... 18.175 family-member-history-sister-jenny-m
.... 18.176 family-member-history-uncle-jenny-m
.... 18.177 figo-stage-IIIA
.... 18.178 genomic-region-studied-jenny-m
.... 18.179 genomic-region-studied-stk11
.... 18.180 genomic-variant-fusion
.... 18.181 genomic-variant-germline-deletion
.... 18.182 genomic-variant-jenny-m
.... 18.183 genomic-variant-somatic-single-nucleotide
.... 18.184 genomics-report-jenny-m
.... 18.185 genomics-report-john-anyperson
.... 18.186 gleason-grade-group-4
.... 18.187 gx-cancer-patient-adam-anyperson
.... 18.188 gx-genomic-bundle-adam-anyperson
.... 18.189 gx-genomic-diagnostic-implication-bap1
.... 18.190 gx-genomic-diagnostic-implication-pof1b
.... 18.191 gx-genomic-diagnostic-implication-polrmt
.... 18.192 gx-genomic-msi
.... 18.193 gx-genomic-specimen-tumornormal-normal
.... 18.194 gx-genomic-specimen-tumornormal-tumor
.... 18.195 gx-genomic-therapeutic-implication-alectinib
.... 18.196 gx-genomic-therapeutic-implication-brigatinib
.... 18.197 gx-genomic-therapeutic-implication-ceritinib
.... 18.198 gx-genomic-therapeutic-implication-crizotinib
.... 18.199 gx-genomic-therapeutic-implication-lorlatinib
.... 18.200 gx-genomic-tmb
.... 18.201 gx-genomic-variant-fusion-met-alk
.... 18.202 gx-genomic-variant-pertinent-negative-nras-kit-braf
.... 18.203 gx-genomic-variant-somatic-bap1-indel
.... 18.204 gx-genomic-variant-somatic-cdkn2a-cnv
.... 18.205 gx-genomic-variant-somatic-cdkn2b-cnv
.... 18.206 gx-genomic-variant-somatic-kdm5d
.... 18.207 gx-genomic-variant-somatic-mtap
.... 18.208 gx-genomic-variant-somatic-mycn
.... 18.209 gx-genomic-variant-somatic-pof1b
.... 18.210 gx-genomic-variant-somatic-polrmt
.... 18.211 gx-genomics-report-adam-anyperson
.... 18.212 gx-order-tumornormal-gensop-inc
.... 18.213 gx-practitioner-test-pathologist
.... 18.214 gx-us-core-organization-gensop-inc
.... 18.215 history-of-cancer-metastatic-to-liver
.... 18.216 hodgkins-lymphoma-stage-IIIe
.... 18.217 human-specimen-left-breast-jenny-m
.... 18.218 human-specimen-lung
.... 18.219 jenny-m-chest-wall-lymph-nodes-treatment-volume
.... 18.220 jenny-m-chest-wall-treatment-volume
.... 18.221 john-anyperson-chf
.... 18.222 john-anyperson-treatment-volume
.... 18.223 karnofsky-performance-status-normal-activity
.... 18.224 lab-result-observation-hemoglobin
.... 18.225 mCODE Patient Group Example
.... 18.226 mcode-patient-bundle-jenny-m
.... 18.227 melanoma-breslow-depth-stage
.... 18.228 melanoma-clark-level-4
.... 18.229 multiple-myeloma-iss-stage-II
.... 18.230 multiple-myeloma-riss-stage-II
.... 18.231 no-history-of-metastatic-cancer
.... 18.232 observation-smoking-pack-years-jenny-m
.... 18.233 primary-cancer-condition-breast
.... 18.234 primary-cancer-condition-cll
.... 18.235 primary-cancer-condition-jenny-m
.... 18.236 primary-cancer-condition-nonspecific
.... 18.237 primary-cancer-condition-nsclc
.... 18.238 radiotherapy-treatment-summary-chest-wall-jenny-m
.... 18.239 radiotherapy-treatment-summary-other-with-text
.... 18.240 rai-stage-II
.... 18.241 secondary-cancer-condition-brain-mets
.... 18.242 tnm-clinical-distant-metastases-category-cM0
.... 18.243 tnm-clinical-distant-metastases-category-jenny-m
.... 18.244 tnm-clinical-primary-tumor-category-cT3
.... 18.245 tnm-clinical-primary-tumor-category-jenny-m
.... 18.246 tnm-clinical-regional-nodes-category-cN3
.... 18.247 tnm-clinical-regional-nodes-category-jenny-m
.... 18.248 tnm-clinical-stage-group-3c
.... 18.249 tnm-clinical-stage-group-jenny-m
.... 18.250 tnm-pathologic-distant-metastases-category-jenny-m
.... 18.251 tnm-pathologic-primary-tumor-category-jenny-m
.... 18.252 tnm-pathologic-regional-nodes-category-jenny-m
.... 18.253 tnm-pathologic-stage-group-jenny-m
.... 18.254 tumor-lobular-carcinoma-left-breast
.... 18.255 tumor-marker-test-egf
.... 18.256 tumor-marker-test-er-jenny-m
.... 18.257 tumor-marker-test-her2-jenny-m
.... 18.258 tumor-marker-test-oncotype-dx-jenny-m
.... 18.259 tumor-marker-test-pr-jenny-m
.... 18.260 tumor-size-jenny-m
.... 18.261 tumor-size-pathology
.... 18.262 tumor-specimen-left-breast-jenny-m
.... 18.263 tumor-specimen-lobular-carcinoma-left-breast
.... 18.264 us-core-condition-anxiety-jenny-m
.... 18.265 us-core-condition-depression-jenny-m
.... 18.266 us-core-condition-hypertension-jenny-m
.... 18.267 us-core-diagnosticreport-lab-jenny-m
.... 18.268 us-core-observation-lab-neutrophils-jenny-m
.... 18.269 us-core-observation-lab-sentinel-nodes-jenny-m
.... 18.270 us-core-observation-lab-tumor-dcis-jenny-m
.... 18.271 us-core-observation-lab-tumor-grade-jenny-m
.... 18.272 us-core-observation-lab-tumor-invasion-jenny-m
.... 18.273 us-core-observation-lab-tumor-margins-jenny-m
.... 18.274 us-core-organization-bedrock-medicine
.... 18.275 us-core-organization-physician-services-inc
.... 18.276 us-core-practitioner-jane-radiotech
.... 18.277 us-core-practitioner-kyle-anydoc
.... 18.278 us-core-practitioner-mary-obgyn
.... 18.279 us-core-practitioner-nancy-oncology-nurse
.... 18.280 us-core-practitioner-owen-oncologist
.... 18.281 us-core-practitioner-peter-pathologist
.... 18.282 us-core-procedure-biopsy-jenny-m
.... 18.283 us-core-procedure-mammogram-jenny-m
.... 18.284 us-core-smokingstatus-jenny-m
... 19 Basic Examples
... 20 Genomics Examples
... 21 Extended Example
... 22 Release Notes
... 23 Glossary
... 24 Download Specification